Integrated Filing — IndAS

General information about company
Scrip Code	524470
NSE Symbol	SYNCOMF
MSEI Symbol	NOTLISTED
ISIN	INE312C01025
Name of company	Syncom Formulations (India) Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	19-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	13-May-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Multi segment
Description of single segment
Start date and time of board meeting	19-May-2025   16:00:00
End date and time of board meeting	19-May-2025   17:45:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	2022-02-14
Indicate Company website link for updated RPT policy of the Company	https://syncomformulations.com/sfil/wp-content/uploads/2022/12/08Amended-RPT-Policy-dated-14.02.2022.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
NO DEFAULT ON LOANS AND DEBT

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	1484633000	4628493000
	Other income	69031000	171912000
	Total income	1553664000	4800405000
2	Expenses
(a)	Cost of materials consumed	801605000	2780293000
(b)	Purchases of stock-in-trade	156848000	394771000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	43880000	-106224000
(d)	Employee benefit expense	149747000	521737000
(e)	Finance costs	892000	8502000
(f)	Depreciation, depletion and amortisation expense	12864000	51939000
(f)	Other Expenses
1	OTHER EXPENSES	157833000	502863000
	Total other expenses	157833000	502863000
	Total expenses	1323669000	4153881000
3	Total profit before exceptional items and tax	229995000	646524000
4	Exceptional items	82000	58000
5	Total profit before tax	230077000	646582000
6	Tax expense
7	Current tax	45012000	144526000
8	Deferred tax	10045000	13338000
9	Total tax expenses	55057000	157864000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	175020000	488718000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	175020000	488718000
17	Other comprehensive income net of taxes	-22819000	45802000
18	Total Comprehensive Income for the period	152201000	534520000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	940000000	940000000
	Face value of equity share capital	1	1
27	Details of debt securities
22	Reserves excluding revaluation reserve		2459038000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	0.16	0.57
	Diluted earnings (loss) per share from continuing operations	0.16	0.57
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	0.16	0.57
	Diluted earnings (loss) per share from continuing and discontinued operations	0.16	0.57
24	Debt equity ratio	0	0
25	Debt service coverage ratio	0	0
26	Interest service coverage ratio	0	0
27	Disclosure of notes on financial results

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	775261000
	Capital work-in-progress	0
	Investment property	473344000
	Goodwill	0
	Other intangible assets	472000
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets
	Non-current investments	36482000
	Trade receivables, non-current
	Loans, non-current	0
	Other non-current financial assets	128529000
	Total non-current financial assets	165011000
	Deferred tax assets (net)	0
	Other non-current assets	8158000
	Total non-current assets	1422246000
2	Current assets
	Inventories	412929000
	Current financial asset
	Current investments	892164000
	Trade receivables, current	1069443000
	Cash and cash equivalents	6923000
	Bank balance other than cash and cash equivalents	0
	Loans, current	53929000
	Other current financial assets	35322000
	Total current financial assets	2057781000
	Current tax assets (net)	0
	Other current assets	203910000
	Total current assets	2674620000
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	4096866000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	940000000
	Other equity	2459038000
	Total equity attributable to owners of parent	3399038000
	Non controlling interest
	Total equity	3399038000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	0
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	13335000
	Total non-current financial liabilities	13335000
	Provisions, non-current	41684000
	Deferred tax liabilities (net)	63105000
	Deferred government grants, Non-current	0
	Other non-current liabilities	0
	Total non-current liabilities	118124000
	Current liabilities
	Current financial liabilities
	Borrowings, current	40432000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	227889000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	199330000
	Total Trade payable	427219000
	Other current financial liabilities	21300000
	Total current financial liabilities	488951000
	Other current liabilities	49568000
	Provisions, current	41185000
	Current tax liabilities (Net)	0
	Deferred government grants, Current	0
	Total current liabilities	579704000
3	Liabilities directly associated with assets in disposal group classified as held for sale
4	Regulatory deferral account credit balances and related deferred tax liability
	Total liabilities	697828000
	Total equity and liabilites	4096866000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
1	Pharmaceuticals Drugs & Formulations	1521489000	4678492000
2	Trading of Commodities	21345000	82584000
3	Renting of Property	10830000	39329000
	Total Segment Revenue	1553664000	4800405000
	Less: Inter segment revenue	0	0
	Revenue from operations	1553664000	4800405000
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
1	Pharmaceuticals Drugs & Formulations	220569000	616990000
2	Trading of Commodities	419000	2035000
3	Renting of Property	9981000	36059000
	Total Profit before tax	230969000	655084000
	i. Finance cost	892000	892000
	ii. Other Unallocable Expenditure net off Unallocable income	0	0
	Profit before tax	230077000	646582000
3	(Segment Asset - Segment Liabilities)
	Segment Asset
1	Pharmaceuticals Drugs & Formulations	3575201000	3575201000
2	Trading of Commodities	44867000	44867000
3	Renting of Property	476798000	476798000
	Total Segment Asset	4096866000	4096866000
	Un-allocable Assets	0	0
	Net Segment Asset	4096866000	4096866000
4	Segment Liabilities
	Segment Liabilities
1	Pharmaceuticals Drugs & Formulations	675447000	675447000
2	Trading of Commodities	8276000	8276000
3	Renting of Property	14104000	14104000
	Total Segment Liabilities	697827000	697827000
	Un-allocable Liabilities	0	0
	Net Segment Liabilities	697827000	697827000
	Disclosure of notes on segments	Textual Information(2)

Text Block

Textual Information(2)

Notesttttt nThe above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 19052025ttttt nThese above results have been prepared in compliance with the Indian Accounting Standard referred to as Ind AS as notified prescribed under Section 133 of the Companies Act 2013 read with Companies Indian Accounting Standards Rules 2015 as amended from time to timettttt n3The company is operating in 3 segments ie a Pharmaceuticals Drugs & Formulations b Trading of Commodities c Renting of Property particulars of segment wise results are given as required.ttttt nThe Standalone Statement of Assets and Liabilities as at 31st March 2025 and the Standalone Statement of Cash Flow is provided as an annexure to this statement.ttttt nAs required under Regulation 33 of SEBI LODR Regulations 2015 the Auditors report provided by the Statutory Auditors have carried out Audit books of Accounts for the Financial year 2024-2025 and issued us an Audit Report with an unmodified opinion on Audited financial Results for the Quarter Year ended 31st March 2025 Therefor the company is not required to give statement of Impact of Audit Qualification for Audit report with modified opinionttttt nPrevious period figures have been regroupedreclassified wherever necessary to confirm to this period classification. ttttt nThe figures of the Last Quarter are the balancing figures between the audited figures in respect of full financial year the published year to date figures upto 3rd quarter of that financial yearttttt n

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
	Total Amount of items that will not be reclassified to profit and loss
2	Income tax relating to items that will not be reclassified to profit or loss	0	0
3	Amount of items that will be reclassified to profit and loss
1	Items that will be reclassified to profit and loss account	-22819000	45802000
	Total Amount of items that will be reclassified to profit and loss	-22819000	45802000
4	Income tax relating to items that will be reclassified to profit or loss	0	0
5	Total Other comprehensive income	-22819000	45802000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Standalone
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			646582000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			8502000
	Adjustments for decrease (increase) in inventories			-202114000
	Adjustments for decrease (increase) in trade receivables, current			-137297000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			-114049000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			-10996000
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			284909000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			13764000
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			48025000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			6639000
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			-62000
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			0
	Adjustments for dividend income			0
	Adjustments for interest income			0
	Adjustments for share-based payments			0
	Adjustments for fair value losses (gains)			0
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			0
	Other adjustments to reconcile profit (loss)			-166244000
	Other adjustments for non-cash items			0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			-268923000
	Net cash flows from (used in) operations			377659000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			144526000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			233133000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			0
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			0
	Purchase of property, plant and equipment			99593000
	Proceeds from sales of investment property			0
	Purchase of investment property			217767000
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			0
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			133572000
	Net cash flows from (used in) investing activities	-183788000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			0
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			-676071000
	Repayments of borrowings			0
	Payments of lease liabilities			0
	Dividends paid			0
	Interest paid			8502000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			8646000
	Net cash flows from (used in) financing activities			-675927000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			-626582000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			0
	Net increase (decrease) in cash and cash equivalents			-626582000
	Cash and cash equivalents cash flow statement at beginning of period			633505000
	Cash and cash equivalents cash flow statement at end of period			6923000